PDCD1 and head and neck squamous cell carcinoma: In 2021, a meta-analysis conducted on seven studies including 814 R/M HNSCC patients treated with PD-1 or PD-L1 inhibitors as single agents found that HPV-positive HNSCC patients displayed significantly longer OS than HPV-negative HNSCC patients.